Tag: neurostimulation
Magnus highlights new SAINT clinical data at 2024 NYC Neuromodulation Conference
Magnus Medical has announced promising new clinical data on its Stanford accelerated intelligent neuromodulation therapy (SAINT) at the 2024 NYC Neuromodulation Conference (31 July–4...
Nalu Medical closes US$85 million Series E financing round
Nalu Medical has announced the closing of an incremental US$20 million in equity financing from new investor B Capital, bringing its total Series E...
Tivic completes enrolment in study of non-invasive, bioelectronic VNS therapy
Tivic Health Systems has announced that enrolment in its pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation (VNS) has been completed....
Flexible nanoelectrodes can “pave the way” for higher-resolution stimulation devices
Engineers at Rice University (Houston, USA) have created nanoelectrodes that are minimally invasive and exceptionally flexible—and, as such, have the potential to function as...
Nalu Medical announces first enrolment in peripheral nerve stimulation RCT
Nalu Medical has announced the first patient enrolment in the COMFORT-2 randomised controlled trial (RCT), which will assess the company’s peripheral nerve stimulation (PNS)...
Magnus receives US FDA clearance for SAINT neuromodulation system in severe...
Magnus Medical has announced receipt of 510(k) clearance from the US Food and Drug Administration (FDA) for its SAINT neuromodulation system for the treatment of...
Abbott introduces Canada’s first remote neuromodulation patient-care technology
Abbott recently announced the Health Canada licensing of NeuroSphere virtual clinic, a remote programming technology that the company claims is the first of its kind...
Registration opens for 15th International Neuromodulation Society congress in Barcelona
At the International Neuromodulation Society (INS) 15th world congress (21–26 May 2022; Barcelona, Spain), researchers from over 40 countries will present plenary lectures and...
Updated medical policy expands patient access to Abbott’s DRG stimulation technology
Abbott announced today that UnitedHealthcare (UHC)—the largest private health insurance company in the USA—has updated its ‘Implanted electrical stimulator for spinal cord’ medical policy...
Galvani Bioelectronics announces first investigational treatment of rheumatoid arthritis using splenic...
Galvani Bioelectronics has announced that the first patient with rheumatoid arthritis (RA) has been treated through stimulation of the splenic nerve using its novel...
Mainstay Medical announces positive efficacy and safety outcomes from ReActiv8-B trial
Mainstay Medical has announced the publication of two-year patient outcomes data from its pivotal ReActiv8-B clinical trial. The data, which are published in Neuromodulation:...
US physicians “among nation’s first” to implant neurostimulator technology for advanced...
Doctors at St David's Medical Center in Austin, USA recently implanted a new neurostimulator technology in patients to help treat advanced heart failure—and are...
BlueWind Medical completes patient enrolment in OASIS study
BlueWind Medical has announced the successful completion of patient enrolment in the OASIS pivotal clinical study that will assess the company’s innovative Renova iStim...
Rune Labs and Medtronic partner to improve understanding of neurostimulation with...
Rune Labs, a company using aggregated brain data to empower the development and delivery of precision medicines for neurological and psychiatric diseases, and global healthcare...
Magnus Medical announces Breakthrough Device designation for novel depression treatment and...
Magnus Medical has announced that the US Food and Drug Administration (FDA) has granted the company Breakthrough Device designation for its individualised, rapid-acting, non-invasive...
Neuvotion secures more than US$1 million in seed funding to commercialise...
Neuvotion has announced that it has received more than US$1 million in seed funding. The Long Island Angel Network, an organised group of individual,...
CRISP study indicates clinical benefit of non-paraesthesia-based approaches in burst SCS...
The CRISP (Comparison of paraesthesia mapping to anatomic midline-based burst programming strategies) study, published in Neuromodulation: Technology at the Neural Interface, has found that...
NeuroOne Medical Technologies gains FDA 510(k) clearance for Evo SEEG electrode
NeuroOne Medical Technologies—a company focused on improving surgical care options and outcomes for patients with neurological disorders—has announced that it has received US Food...
Allegheny Health Network initiates clinical trial exploring use of DBS to...
A team of physicians at Allegheny Health Network (AHN) in Pittsburgh, USA has received US Food and Drug Administration (FDA) approval to begin the...
Long-term effectiveness of STN-DBS for Parkinson’s confirmed with 15-year follow-up study
New findings published in Neurology, the medical journal of the American Academy of Neurology (AAN), have confirmed the long-term effectiveness of deep brain stimulation...
Nevro announces FDA approval of 10kHz high-frequency SCS therapy for painful...
Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system for the treatment of chronic pain associated with...
BlueWind Medical enrols 100th patient in OASIS study of Renova iStim...
BlueWind Medical, a company making neuromodulation medical devices for the treatment of overactive bladder, has announced that the 100th patient has been enrolled in...
Mainstay Medical launches implantable restorative neurostimulation system in USA
Mainstay Medical has announced the limited US commercial launch of ReActiv8, its implantable restorative neurostimulation system to treat intractable chronic low back pain. The...
Medtronic announces FDA approval of recharge-free Vanta spinal cord stimulation implant
Medtronic has received US Food and Drug Administration (FDA) approval for Vanta—a high-performance, recharge-free implantable neurostimulator (INS) with a device life that can be...
FDA approves Percept PC neurostimulator with BrainSense technology
Medtronic has announced it received US Food and Drug Administration (FDA) approval for the Percept PC deep brain stimulation (DBS) system. BrainSense technology makes...
Axonics wins FDA approval for its next-generation implantable neurostimulator
Axonics has announced the US Food and Drug Administration (FDA) approval of its next-generation rechargeable implantable neurostimulator for its r-SNM system under a premarket approval...
Over-the-skin electrical stimulation helps provide movement in quadriplegics
Researchers at The Feinstein Institutes for Medical Research used new closed-loop neurostimulation methods and textile-based electrodes to facilitate individual finger movement and grasp force...
Axonics announces first commercial US patient implanted with its sacral neuromodulation...
Axonics has announced the first US-based implantation of the Axonics r-SNM system subsequent to its clearance by the US Food & Drug Administration (FDA)...
Axonics granted full-body MR-conditional CE mark for its sacral neuromodulation system
Axonics has announced that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging conditional labelling for the Axonics r-SNM...
Stimwave address patent infringement lawsuit brought by Nevro
Stimwave issued a statement today in response to a complaint made by Nevro in Federal Court Delaware District last week alleging Stimwave is infringing...
The future of neurostimulation: Smart neuromodulation
Better understanding of the brain alongside the integration of artificial intelligence may represent the future of neuromodulation. From machine learning and novel technology to...
Nuvectra receives FDA head-only MR-conditional approval for Algovita
Nuvectra has announced that it has received US Food and Drug Administration (FDA) head-only MR-conditional approval for the company’s Algovita spinal cord stimulation (SCS) system.
Scott...
Mainstay Medical announces headline results from ReActiv8-B clinical study
Mainstay Medical International, a medical device company focused on commercialising ReActiv8, an implantable restorative neurostimulation system designed to treat an underlying cause of disabling...
Mainstay Medical announces the completion of all implants in the ReActiv8-B...
Mainstay Medical International, a medical device company focused on bringing to market ReActiv8, an implantable neurostimulation system to treat chronic low back pain, announces...
Neurostimulation can be part of the solution to the opioid crisis
The president of the United States of America has recently declared the opioid crisis in that country a “public health emergency”. In light of...
Flexible battery could revolutionise implanted devices
Experts at Queen’s University Belfast, Belfast, UK, have designed a flexible battery that could provide an alternative to the rigid batteries that usually power...
Neurostimulation protocol reduces spasticity in spinal cord injury
Spasticity is a common disorder experienced by patients with spinal cord injuries (SCI). Previous studies have shown that excitatory repetitive transcranial magnetic stimulation (rTMS)...
Wireless stimulation may ease migraine pain as well as drugs
A preliminary study suggests that a new, wireless patch that you wear on your arm may help reduce migraine pain as well as drugs....
